Obesity drug pulled over suicide risks. The drug, Acomplia, increases the risk of depression and anxiety in overweight or obese patients. The European Medicines Evaluation Agency recommended suspension of the drug yesterday amid concerns that it may increase depression, sleep disorders, anxiety and aggression in some overweight or obese patients. As the patients at risk cannot be identified, marketing of the drug should be suspended, the EMEA said.
Link to ArticleAdditional Stories
Users of slimming drug at risk of psychiatric disorders - The Times 24th October 2008
Banned: The obesity drug linked to suicide - Daily Mail 24th October 2008Anti-obesity drug use suspended - BBC Health News 23rd October 2008
0 comments:
Post a Comment